These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 36016185)

  • 1. Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2.
    García-Alanis M; Morales-Cárdenas M; Toapanta-Yanchapaxi LN; Chiquete E; Núñez I; Ceballos-Liceaga SE; Carbajal-Sandoval G; Toledo-Salinas C; Mendoza-Hernández DA; Scheffler-Mendoza SC; Ortega-Martell JA; Carrillo-García DA; Hernández-Valdivia N; Gutiérrez-Romero A; Galnares-Olalde JA; Flores-Silva FD; Díaz-Ortega JL; Reyes-Terán G; López-Gatell H; Cortes-Alcalá R; Pérez-Padilla JR; Arauz A; García-Grimshaw M; Valdés-Ferrer SI
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.
    López-Mena D; García-Grimshaw M; Saldivar-Dávila S; Hernandez-Vanegas LE; Saniger-Alba MDM; Gutiérrez-Romero A; Carrillo-Mezo R; Valdez-Ruvalcaba HE; Cano-Nigenda V; Flores-Silva FD; Cantú-Brito C; Santibañez-Copado AM; Diaz-Ortega JL; Ceballos-Liceaga SE; Murillo-Bonilla LM; Sepulveda-Núñez AI; García-Talavera V; Gonzalez-Guerra E; Cortes-Alcala R; Lopez-Gatell H; Carbajal-Sandoval G; Reyes-Terán G; Valdés-Ferrer SI; Arauz A
    Neurology; 2022 May; 98(19):e1933-e1941. PubMed ID: 35277439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program.
    Toledo-Salinas C; Scheffler-Mendoza SC; Castano-Jaramillo LM; Ortega-Martell JA; Del Rio-Navarro BE; Santibáñez-Copado AM; Díaz-Ortega JL; Baptista-Rosas R; Sánchez-Novoa P; García-Grimshaw M; Valdés-Ferrer SI; Reyes-Terán G; Mendoza-Hernández DA
    J Clin Immunol; 2022 Nov; 42(8):1593-1599. PubMed ID: 35976470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.
    Romero-Ibarguengoitia ME; González-Cantú A; Pozzi C; Levi R; Mollura M; Sarti R; Sanz-Sánchez MÁ; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; Del Rio-Parra GF; Barco-Flores IA; González-Facio R; Azzolini E; Barbieri R; de Azevedo Dias AR; Henriques Guimarães Júnior M; Bastos-Borges A; Acciardi C; Paez-Bo G; Teixeira MM; Rescigno M
    Front Immunol; 2022; 13():894277. PubMed ID: 35967368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events following immunization and psychological distress among cancer patients/survivors following vaccination against SARS-CoV-2 infection.
    Wong LP; Lai LL; See MH; Alias H; Syed Omar SF; Ng CG; Ho GF; Ong TA; Wong YC; Ooi PL; Elias JM; Hu Z; Lin Y
    Front Psychol; 2022; 13():906067. PubMed ID: 35959016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future.
    Hamayoun M; Abdulrazak I; Farid M; Malik MR; Mohamud MF
    IJID Reg; 2022 Sep; 4():47-52. PubMed ID: 35720961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais.
    Silva RBD; Silva TPRD; Sato APS; Lana FCF; Gusmão JD; Souza JFA; Matozinhos FP
    Rev Saude Publica; 2021; 55():66. PubMed ID: 34706042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory Longitudinally Extensive Transverse Myelitis after Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in a Japanese Man.
    Miyaue N; Yoshida A; Yamanishi Y; Tada S; Ando R; Hosokawa Y; Yabe H; Nagai M
    Intern Med; 2022 Mar; 61(5):739-742. PubMed ID: 34897155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality.
    Martins-Filho PR; Santana RRR; Cavalcante TF; Barboza WS; de Souza MF; Góes MAO; Fontes ÂMB; da Silva MEL; Tanajura DM
    Rev Panam Salud Publica; 2022; 46():e110. PubMed ID: 36016838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.